Financials Global Bioenergies

Equities

Market Closed - Euronext Paris Other stock markets 11:15:45 2024-06-07 am EDT			5-day change	1st Jan Change
1.984 ^EUR	-1.05%		+0.20%	-1.78%

May. 29	Global Bioenergies Announces Completion of the Basic Engineering Phase and Success of the Related Test Campaign	CI
Apr. 09	Global Bioenergies Receives EUR70 Million Indicative Orders for New Plant	MT

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	32.4	69.71	56.18	44.41	36.55	35.96	-	-
Enterprise Value (EV) ¹	25.17	68.03	42.45	46.96	37.15	42.66	49.91	53.06
P/E ratio	-2.55 x	-6.98 x	-6.27 x	-3.74 x	-4.21 x	-3.61 x	-3.71 x	-7.94 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	9.27 x	21.3 x	14.5 x	25.9 x	4.1 x	20.6 x	17.5 x	9.46 x
EV / Revenue	7.2 x	20.8 x	10.9 x	27.4 x	4.17 x	24.4 x	24.3 x	14 x
EV / EBITDA	-2.39 x	-6.96 x	-3.83 x	-4.13 x	-5.4 x	-5.33 x	-6.01 x	-10 x
EV / FCF	-2.39 x	-6.03 x	-2.88 x	-3.88 x	-	-3.44 x	-3.38 x	-1.51 x
FCF Yield	-41.8%	-16.6%	-34.7%	-25.8%	-	-29.1%	-29.6%	-66.3%
Price to Book	3.34 x	18.8 x	-	-	-	-3.89 x	-1.67 x	-
Nbr of stocks (in thousands)	8,709	9,077	11,349	14,854	18,092	18,127	-	-
Reference price ²	3.720	7.680	4.950	2.990	2.020	1.984	1.984	1.984
Announcement Date	3/11/20	3/15/21	3/2/22	2/14/23	3/6/24	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	3.494	3.276	3.881	1.715	8.91	1.75	2.05	3.8
EBITDA ¹	-10.53	-9.777	-11.09	-11.37	-6.878	-8	-8.3	-5.3
EBIT ¹	-14.02	-13.06	-13.35	-13.19	-9.711	-10.65	-11.25	-10.5
Operating Margin	-401.37%	-398.53%	-343.93%	-769.21%	-108.99%	-608.57%	-548.78%	-276.32%
Earnings before Tax (EBT)	-	-13.41	-	-	-	-	-	-
Net income ¹	-12.74	-11.15	-11.77	-11.99	-8.656	-6.9	-8.2	-9.6
Net margin	-364.65%	-340.29%	-303.35%	-698.89%	-97.15%	-394.29%	-400%	-252.63%
EPS ²	-1.460	-1.100	-0.7900	-0.8000	-0.4800	-0.5500	-0.5350	-0.2500
Free Cash Flow ¹	-10.51	-11.29	-14.72	-12.1	-	-12.4	-14.75	-35.2
FCF margin	-300.83%	-344.62%	-379.33%	-705.61%	-	-708.57%	-719.51%	-926.32%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	3/11/20	3/15/21	3/2/22	2/14/23	3/6/24	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	2.55	0.61	6.7	14	17.1
Net Cash position ¹	7.23	1.68	13.7	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-0.2239 x	-0.0883 x	-0.8375 x	-1.681 x	-3.226 x
Free Cash Flow ¹	-10.5	-11.3	-14.7	-12.1	-	-12.4	-14.8	-35.2
ROE (net income / shareholders' equity)	-159%	-161%	-94.1%	-44.9%	-	-	-	-
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-	-
Book Value Per Share ²	1.110	0.4100	-	-	-	-0.5100	-1.190	-
Cash Flow per Share ²	-1.180	-1.050	-0.8000	-0.6800	-	-0.6200	-0.6400	-
Capex ¹	0.24	0.61	2.85	1.95	-	3.5	10	30
Capex / Sales	6.9%	18.54%	73.33%	113.8%	-	200%	487.8%	789.47%
Announcement Date	3/11/20	3/15/21	3/2/22	2/14/23	3/6/24	-	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.984 EUR

Average target price

2.6 EUR

Spread / Average Target

+31.05%

	1st Jan change	Capi.
GLOBAL BIOENERGIES	-1.78%	38.87M
THERMO FISHER SCIENTIFIC	+9.48%	222B
DANAHER CORPORATION	+13.72%	195B
INTUITIVE SURGICAL, INC.	+23.79%	148B
BOSTON SCIENTIFIC CORPORATION	+33.39%	113B
SIEMENS HEALTHINEERS AG	+4.75%	66.45B
EDWARDS LIFESCIENCES CORPORATION	+15.59%	53.11B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.16%	50.03B
AGILENT TECHNOLOGIES, INC.	-4.35%	38.8B
GE HEALTHCARE TECHNOLOGIES INC.	-1.27%	34.85B